Valuation: Starpharma Holdings Limited

Market Cap 291M 203M 178M 166M 152M 286M 19.57B 1.97B 770M 9.62B 763M 746M 33.26B P/E 2026 *
-0.86x
P/E 2027 * -
Enterprise Value 280M 196M 172M 160M 147M 276M 18.84B 1.9B 741M 9.26B 735M 719M 32.03B EV / Sales 2026 *
17.7x
EV / Sales 2027 * 11.7x
Free-Float
58.46%
Yield 2026 *
-
Yield 2027 * -
1 day-0.72%
1 week-2.82%
Current month-1.43%
3 months-4.17%
6 months+97.14%
Current year+91.67%
1 week 0.69
Extreme 0.69
0.72
1 month 0.65
Extreme 0.65
0.78
Current year 0.33
Extreme 0.33
0.79
1 year 0.09
Extreme 0.094
0.79
3 years 0.08
Extreme 0.082
0.79
5 years 0.08
Extreme 0.082
1.5
10 years 0.08
Extreme 0.082
2.52
Manager TitleAgeSince
Chief Executive Officer - 2024-01-07
Director of Finance/CFO - 2023-04-02
Human Resources Officer - 2022-05-31
Director TitleAgeSince
Chairman 81 2014-06-12
Director/Board Member 55 2020-02-29
Director/Board Member - 2021-07-31
Date Insider Type Main position Quantity % Market Cap.
12/17/25 Free

Chief Executive Officer

6,525,939 1.5604%
10/21/25 Buy

Chairman

450,000 0.1076%
10/6/23 Expiration

Chief Executive Officer

514,918 0.1254%
Change 5-day change 1-year change 3-year change Capi.($)
-0.72%-2.82%+618.75%+91.67% 203M
+0.86%+1.43%+47.17%+161.40% 1,067B
+1.59%+4.09%+56.51%+52.79% 635B
+0.95%+1.91%+36.30%+83.13% 458B
+1.60%+6.25%+37.00%+30.00% 347B
-0.60%+1.52%+36.67%+39.80% 295B
-0.14%+0.60%+17.29%+18.19% 262B
+0.09%-2.82%-29.09%-41.29% 216B
+1.22%+2.66%+22.66%+59.81% 203B
-1.18%-3.70%+11.28%+67.43% 161B
Average +0.37%+0.91%+85.45%+56.29% 364.37B
Weighted average by Cap. +0.76%+1.95%+36.03%+78.15%

Financials

2026 *2027 *
Net sales 15.8M 11.05M 9.7M 9.02M 8.28M 15.56M 1.06B 107M 41.87M 523M 41.48M 40.58M 1.81B 24M 16.78M 14.74M 13.71M 12.58M 23.64M 1.62B 163M 63.6M 795M 63M 61.65M 2.75B
Net income -3.6M -2.52M -2.21M -2.06M -1.89M -3.55M -242M -24.42M -9.54M -119M -9.45M -9.25M -412M 100K 69.93K 61.42K 57.12K 52.41K 98.48K 6.73M 678K 265K 3.31M 263K 257K 11.45M
Net Debt -10.8M -7.55M -6.63M -6.17M -5.66M -10.64M -727M -73.25M -28.62M -358M -28.35M -27.74M -1.24B -10.8M -7.55M -6.63M -6.17M -5.66M -10.64M -727M -73.25M -28.62M -358M -28.35M -27.74M -1.24B
Logo Starpharma Holdings Limited
Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology. The Company's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The Company's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. It also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The Company has applied its DEP technology to the innovative area of antibody-drug conjugates.
Employees
40
Date Price Change Volume
26-07-24 A$0.6900 -0.72% 1,831,701
26-07-23 A$0.6950 0.00% 1,268,002
26-07-22 A$0.6950 -0.71% 1,948,830
26-07-21 A$0.7000 -1.41% 1,058,471
26-07-20 A$0.7100 0.00% 911,988
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.6900AUD
Average target price
0.8000AUD
Spread / Average Target
+15.94%

Annual profits - Rate of surprise